Latest News

Uniseed makes new investment into drug development company Exonate Ltd

  Uniseed makes £200,000 investment in Exonate as part of £1.5 million round from existing and new investors Exonate awarded £4.9 million from the Wellcome Trust ‐ Seeding Drug Discovery Initiative Program to develop eye drop treatment for wet age‐related macular...

Exonate receives Wellcome Trust funding

Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)   Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need Cambridge, UK. Monday 6th February 2017 –...

Uniseed co – leads investment round in probiotics drink PERKii

Uniseed makes $1M investment in PERKii from its third and largest fund supported by four Group of 8 Universities and CSIRO. An additional $950K brought in from Uniseed’s network of sophisticated investors, with Uniseed managing these funds on their behalf. PERKii...

Uniseed launches $50 million fund with new investment partners

Uniseed now operating at four of the Group of 8 Universities and CSIRO Early stage investment in all technology sectors Uniseed, a venture fund operating at the Universities of Melbourne, New South Wales and Queensland, is pleased to announce that the University of...

Uniseed Newsletter – September 2015

In this newsletter we talk about two of our investees: Hatchtech and Dr. Reddy’s Laboratories sign US$197 million commercial  agreement for next generation head lice treatment Uniseed investee ProGel Pty Ltd releases Perkii® probiotic drink.  ...

ProGel Pty Ltd releases Perkii® probiotic drink

  Uniseed, UniQuest and Brisbane Angels start-up ProGel has begun test marketing of its patented, low calorie, juice and water probiotic drink (Perkii®) in selected stores in Brisbane and the Gold Coast, including: University of Queensland Lolly Shop Pando Café -...

Verva Pharmaceuticals Signs Deals with Two Biotechs

Verva Pharmaceuticals Limited, a public unlisted Australian biotechnology company developing a novel class of insulin sensitizers to treat patients with diabetes, today announced it had signed separate agreements with two biotechnology companies to sell its...

MEDIA ENQUIRIES
Interested in our investees?
Contact us.